Triple acting antimicrobials that are refractory to resistance development
View Patent ↗Multi-drug resistant superbugs are a persistent problem in modern health care. This invention provides an antimicrobial endolysin-Lysostaphin triple fusion protein, comprising (1) an endolysin CHAP endopeptidase domain, (2) an endolysin amidase domain, and (3) a Lysostaphin glycyl-glycine endopeptidase domain. The domains are derived from two proteins that show antimicrobial synergy when used in combination. The protein has specificity and exolytic activity for the peptidoglycan cell wall of untreated, live Staphylococcus aureus from many growth phases i.e. stationary, logarithmic and biofilm growth. The recombinant triple fusion protein comprising the three functional antimicrobial domains is designed to be refractory to resistance development.
1. A recombinant nucleic acid encoding an antimicrobial staphylococcal endolysin-lysostaphin triple fusion protein, comprising (1) an endolysin CHAP endopeptidase domain, (2) an endolysin amidase domain, and (3) a lysostaphin glycyl-glycine endopeptidase domain, wherein each domain of said fusion protein cuts the peptidoglycan cell wall at a different covalent bond of the peptidoglycan cell wall of live Staphylococcus aureus and said fusion protein has the sequence set forth in SEQ ID NO: 6, 8, 10, 12, or 14.
2. A construct comprising the nucleic acid of claim 1 , wherein said nucleic acid is in operable linkage to a promoter that drives expression in a host cell.
3. A cloning vector comprising the construct of claim 2 .
4. An expression vector comprising the construct of claim 2 .
5. A process for transforming a host cell, comprising stably integrating the nucleic acid of claim 1 or the construct of claim 2 into the host cell.
6. An isolated host cell transformed with the nucleic acid according to claim 1 .
7. An isolated host cell transformed with the construct according to claim 2 .
8. The recombinant nucleic acid of claim 1 wherein said recombinant nucleic acid has the sequence set forth in SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO: 13.
9. The recombinant nucleic acid of claim 1 wherein each domain of said fusion protein has lytic activity in the presence of lytic activity of the other two domains.
10. A method of making a recombinant antimicrobial Staphylococcus —specified endolysin-lysostaphin triple fusion protein, said method comprising steps:
a. introducing into a host cell a nucleic acid or construct encoding an antimicrobial Staphylococcus —specific endolysin-lysostaphin triple fusion protein wherein said fusion protein has the sequence set forth in SEQ ID NO: 6, 8, 10, 12, or 14;
b. culturing said cell under conditions suitable for expression of said fusion protein; and
c. recovering the fusion protein so expressed.